Wednesday, February 1, 1995
Volume:
9Issue:
2
According to the Pharmaceutical Research and Manufacturers of
America, as of 1993, 124 cancer drugs were in some stage of development
at 49 pharmaceutical companies and the National Cancer Institute.
The report was based on an NCI survey. At least 16 of the upcoming
cancer drugs are genetically engineered. Since many of these drugs
are targeted to more than one type of cancer, 223 research projects
are ongoing.